References
- Johnson JA , BurkleyBM, LangaeeTY, Clare-SalzlerMJ, KleinTE, AltmanRB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther.92(4) , 437–439 (2012).
- Scott SA , SangkuhlK, GardnerEE et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90(2) , 328–332 (2011).
- Crews KR , GaedigkA, DunnenbergerHM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2) , 321–326 (2012).
- Johnson JA , GongL, Whirl-CarrilloM et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4) , 625–629 (2011).
- Relling MV , GardnerEE, SandbornWJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3) , 387–391 (2011).